Collaboration Opportunity To Develop a Vaccine Against Nicotine or Arecoline, 56027-56028 [2023-17672]

Download as PDF Federal Register / Vol. 88, No. 158 / Thursday, August 17, 2023 / Notices ddrumheller on DSK120RN23PROD with NOTICES1 hallmark feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Amyloidosis due to aggregation of amyloid-b is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to b-cell dysfunction. Researchers at NIA used a bioinformatic approach to identify two novel islet amyloid polypeptide isoforms: IAPPb, encoding an elongated propeptide and nonaggregating IAPPg, which is processed to mature IAPP25 instead of IAPP37. They developed a quantitative selective reaction monitoring (SRM) proteomic assay to measure the isoform peptide levels in human clinical plasma and CSF from individuals with early AD and found that their levels were significantly reduced. Further, mature IAPP25 derived from IAPPg isoform inhibits fibrillation of IAPP and amyloid-b efficiently in vitro. Potential Commercial Applications: The novel IAPPb and IAPPg isoforms are potential peptidyl therapeutics to counteract with amyloid forming IAPP and amyloid-b in treatments of diabetes and Alzheimer’s disease and serve as blood-based biomarkers for Alzheimer’s disease. Competitive Advantages: • Peptide based anti-amyloid medicine. • Potential market applications for neurodegenerative diseases. Development Stage: Pre-clinical (in vivo validation). Publications: Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer’s Disease and Inhibitors of Amyloid Formation. (PMID 36671553) at https://pubmed.ncbi.nlm.nih.gov/ 36671553/. Meng, Lanxia, et al. Islet amyloid polypeptide triggers a-synuclein pathology in Parkinson’s disease. (PMID 37150314) Dated: August 11, 2023. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2023–17673 Filed 8–16–23; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 21:36 Aug 16, 2023 Jkt 259001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Initial Review Group; Genome Research Study Section GNOM–G—CEGS. Date: November 2–3, 2023. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Room 3180, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sarah Jo Wheelan, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Room 3180, Bethesda, MD 20892, (301) 402–8823, wheelansj@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: August 14, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. 56027 552b(c)(6), title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute Of Mental Health, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors; National Institute of Mental Health. Date: September 20–22, 2023. Time: September 20, 2023, 1:00 p.m. to 5:15 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892. Time: September 21, 2023, 10:00 a.m. to 5:55 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892. Time: September 22, 2023, 10:00 a.m. to 3:10 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892. Contact Person: Jennifer E. Mehren, Ph.D., Scientific Advisor, Division of Intramural Research Programs, National Institute of Mental Health, NIH, 35A Convent Drive, Room GE 412, Bethesda, MD 20892–3747, 301–496–3501, mehrenj@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) [FR Doc. 2023–17713 Filed 8–16–23; 8:45 am] Dated: August 14, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P [FR Doc. 2023–17711 Filed 8–16–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Mental Health. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Collaboration Opportunity To Develop a Vaccine Against Nicotine or Arecoline AGENCY: National Institutes of Health, HHS. ACTION: Notice. The Cancer Prevention Program of the National Cancer Institute (NCI) is seeking a partner in the private SUMMARY: E:\FR\FM\17AUN1.SGM 17AUN1 56028 Federal Register / Vol. 88, No. 158 / Thursday, August 17, 2023 / Notices sector to develop a vaccine directed against nicotine or a related molecule called arecoline, with the goal of reducing or eliminating the craving of such substance(s) in smokers or betel nut users. FOR FURTHER INFORMATION CONTACT: Inquiries relating to this collaboration opportunity should be directed to: Michael Pollack, Ph.D., Supervisory Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Room 1E530, Rockville, MD 20850 (for overnight mail) or Bethesda, MD 20892 (for regular mail), Telephone: (240) 276– 5530; Facsimile: (240) 276–5504; Email: pollackm@mail.nih.gov. SUPPLEMENTARY INFORMATION: The NCI has expertise in the latest technology of vaccine development and agents to enhance immune responses to vaccines, and NCI has the ability to participate in vaccine preclinical and clinical studies. The NCI is seeking a partner with expertise in this area of anti-smoking research and development. Dated: August 11, 2023. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2023–17672 Filed 8–16–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Closed Meetings ddrumheller on DSK120RN23PROD with NOTICES1 Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Special Emphasis Panel; T32 Genomic Training. Date: October 31, 2023. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Human Genome Research Institute, VerDate Sep<11>2014 21:36 Aug 16, 2023 Jkt 259001 6700B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Keith McKenney, Ph.D., Scientific Review Officer, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 3000, Bethesda, MD 20892, (301) 594– 4280, mckenneyk@mail.nih.gov. Name of Committee: National Human Genome Research Institute Special Emphasis Panel; R25 Data Science meeting. Date: November 8, 2023. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Human Genome Research Institute, 6700B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sarah Jo Wheelan, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute for Human Genome Research, National Institutes of Health, 6700B Rockledge Drive, Room 3180, Bethesda, MD 20892, (301) 402–8823, wheelansj@nih.gov. Name of Committee: National Human Genome Research Institute Special Emphasis Panel; R25 Genome Research Undergraduates—R25 ELM Training Modules Genomics Research. Date: December 1, 2023. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Human Genome Research Institute, 6700B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Keith McKenney, Ph.D., Scientific Review Officer, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 3000, Bethesda, MD 20892, (301) 594– 4280, mckenneyk@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: August 14, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–17741 Filed 8–16–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental and Craniofacial Research; Notice of Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Dental and Craniofacial Research Council. The meeting will be open to the public as indicated below, with attendance limited to space available. PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Dental and Craniofacial Research Council. Date: September 12–13, 2023. Closed: September 12, 2023, 4:45 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892. Closed: September 13, 2023, 9:00 a.m. to 10:00 a.m. Agenda: To review and evaluate BSC report to Council. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892. Open: September 13, 2023, 10:00 a.m. to 3:30 p.m. Agenda: Report of the Director, NIDCR and concept clearances. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892. Contact Person: Lynn M. King, Ph.D. Director, Division of Extramural Activities, National Institute of Dental and Craniofacial Research, 6701 Democracy Blvd., Room 960, Bethesda, MD 20892–4878, (301) 594–5006, Lynn.King@nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a governmentissued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www.nidcr.nih.gov/about-us/advisorycommittees/advisory-council, where an E:\FR\FM\17AUN1.SGM 17AUN1

Agencies

[Federal Register Volume 88, Number 158 (Thursday, August 17, 2023)]
[Notices]
[Pages 56027-56028]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-17672]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Collaboration Opportunity To Develop a Vaccine Against Nicotine 
or Arecoline

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Cancer Prevention Program of the National Cancer Institute 
(NCI) is seeking a partner in the private

[[Page 56028]]

sector to develop a vaccine directed against nicotine or a related 
molecule called arecoline, with the goal of reducing or eliminating the 
craving of such substance(s) in smokers or betel nut users.

FOR FURTHER INFORMATION CONTACT: Inquiries relating to this 
collaboration opportunity should be directed to: Michael Pollack, 
Ph.D., Supervisory Technology Transfer Manager, NCI Technology Transfer 
Center, 9609 Medical Center Drive, Room 1E530, Rockville, MD 20850 (for 
overnight mail) or Bethesda, MD 20892 (for regular mail), Telephone: 
(240) 276-5530; Facsimile: (240) 276-5504; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: The NCI has expertise in the latest 
technology of vaccine development and agents to enhance immune 
responses to vaccines, and NCI has the ability to participate in 
vaccine preclinical and clinical studies. The NCI is seeking a partner 
with expertise in this area of anti-smoking research and development.

    Dated: August 11, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2023-17672 Filed 8-16-23; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.